+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Zydelig"

Waldenstrom's Macroglobulinemia - Pipeline Insight, 2025 - Product Thumbnail Image

Waldenstrom's Macroglobulinemia - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Small Lymphocytic Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Small Lymphocytic Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 140 Pages
  • Global
From
Mantle Cell Lymphoma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030 - Product Thumbnail Image

Mantle Cell Lymphoma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • Report
  • August 2022
  • 117 Pages
  • Global
From
Non Hodgkin's Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Non Hodgkin's Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 133 Pages
  • Global
From
Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 133 Pages
  • Global
From
B-Cell Non-Hodgkin Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

B-Cell Non-Hodgkin Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 129 Pages
  • Global
From
B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 131 Pages
  • Global
From
Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032 - Product Thumbnail Image

Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

  • Report
  • September 2023
  • 65 Pages
  • Global
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Zydelig (idelalisib) is a prescription medication used to treat certain types of leukemia. It is a kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. Zydelig is approved for use in adults with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). It is also approved for use in combination with other medications to treat relapsed small lymphocytic lymphoma (SLL). Zydelig is manufactured by Gilead Sciences, Inc., a biopharmaceutical company based in California. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2014. It is available in tablet form and is taken orally. Other companies in the market include Novartis, Celgene, and AbbVie. These companies produce medications for the treatment of leukemia, including targeted therapies, immunotherapies, and chemotherapy. Show Less Read more